Those two companies, along with their larger competitor Novartis (nvs), are developing experimental
chimeric antigen receptor T - cell (CAR - T) technology platforms, which are highly personalized treatments that involve extracting patients» immune cells,
re-engineering them to target their specific cancers, and then pumping these sniper - cells back into the body.
In CAR T therapy, a person's own T cells — disease - fighting immune cells — are removed and sent to a lab where they are genetically
re-engineered to produce
chimeric antigen receptors (CARs) on their surface.